Accumulating evidence has supported MCM7 as a proliferation marker, comparable to the existing ones such as Ki-67 or proliferating cell nuclear antigen (PCNA) in multiple malignancies, including lymphoma,14 colorectal cancer,15 ovary cancer,16 prostate cancer17 and lung cancer.18 Here we confirmed that MCM7 expression could be an independent survival predictor for HCC. Here, PCNA is linked to lymphoma.